Regulation

Denmark rejects Janssen and Genmab drug twice in January

Danish drug regulator the Danish Medicines Council has decided not to recommend Darzalex in two different combination treatments, citing costs and uncertain effects. 
Photo: Bonnerup Claus/Ritzau Scanpix
Photo: Bonnerup Claus/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

During its monthly meeting in January, the Danish Medicines Council has rejected two applications from Janssen, which was seeking indication expansions for cancer drug Darzalex, which was developed in collaboration with Danish biotech firm Genmab.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs